Scholarlink

Background <p>Despite the poor prognosis for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), an optimal treatment strategy remains undefined. Mitoxantrone (MIT) is widely used to treat R/R AML.</p> Methods <p>This prospective, single-center, open-label study assessed the efficacy and toxicity of mitoxantrone hydrochloride liposome (Lipo-MIT)-containing regimen therapy, intensified by adding cytarabine (Ara-C), cyclophosphamide (CTX) or other agents. The primary endpoint was composite complete remission (CRc), including complete remission (CR), complete remission with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS). The secondary endpoints included overall response rate (ORR), event-free survival (EFS), overall survival (OS), and safety.</p> Results <p>We enrolled 20 patients (median, 38.50&#xa0;years; range, 20.00–53.00&#xa0;years) and treated them with a Lipo-MIT-containing regimen from April 29, 2022, to July 11, 2023. Twelve patients (60.00%) achieved CRc after one course of induction therapy, of which MAC (Lipo-MIT, Ara-C, CTX)-based regimen was the most commonly used (12/20, 60.00%) with a CRc rate of 66.67% (8/12). Additionally, 13 patients relapsed after allogeneic stem cell transplantation (allo-HSCT) with a CRc of 69.20% (9/13). The median follow-up time was 6.64&#xa0;months, with a median OS of 9.99&#xa0;months (range, 1.64–19.61; 95% confidence interval [CI], 2.05–17.92). Moreover, 95% patients experienced grade 3/4 hematologic treatment-related adverse events (TRAEs), including anemia (60.0%), thrombocytopenia (60.0%), leukopenia (65.0%), and neutropenia (55.0%). All patients experienced nonhematologic TRAEs, with 14 patients showing grade 3/4 toxicity.</p> Conclusion <p>The Lipo-MIT-based regimens demonstrate preliminary efficacy in R/R AML, particularly in those who relapsed after allo-HSCT, though hematologic toxicity warrants careful monitoring.</p> <p><i>Clinical Trial Registration</i>: Clinicaltrials.gov Identifier: NCT04645199 in November 27, 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月12日

查看全文
  • Ni Lu,
  • Li Liu,
  • Yigeng Cao,
  • Rongli Zhang,
  • Weihua Zhai,
  • Xin Chen,
  • Qiaoling Ma,
  • Donglin Yang,
  • Aiming Pang,
  • Jialin Wei,
  • Yi He,
  • Sizhou Feng,
  • Mingzhe Han,
  • Erlie Jiang

摘要

Background

Despite the poor prognosis for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), an optimal treatment strategy remains undefined. Mitoxantrone (MIT) is widely used to treat R/R AML.

Methods

This prospective, single-center, open-label study assessed the efficacy and toxicity of mitoxantrone hydrochloride liposome (Lipo-MIT)-containing regimen therapy, intensified by adding cytarabine (Ara-C), cyclophosphamide (CTX) or other agents. The primary endpoint was composite complete remission (CRc), including complete remission (CR), complete remission with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS). The secondary endpoints included overall response rate (ORR), event-free survival (EFS), overall survival (OS), and safety.

Results

We enrolled 20 patients (median, 38.50 years; range, 20.00–53.00 years) and treated them with a Lipo-MIT-containing regimen from April 29, 2022, to July 11, 2023. Twelve patients (60.00%) achieved CRc after one course of induction therapy, of which MAC (Lipo-MIT, Ara-C, CTX)-based regimen was the most commonly used (12/20, 60.00%) with a CRc rate of 66.67% (8/12). Additionally, 13 patients relapsed after allogeneic stem cell transplantation (allo-HSCT) with a CRc of 69.20% (9/13). The median follow-up time was 6.64 months, with a median OS of 9.99 months (range, 1.64–19.61; 95% confidence interval [CI], 2.05–17.92). Moreover, 95% patients experienced grade 3/4 hematologic treatment-related adverse events (TRAEs), including anemia (60.0%), thrombocytopenia (60.0%), leukopenia (65.0%), and neutropenia (55.0%). All patients experienced nonhematologic TRAEs, with 14 patients showing grade 3/4 toxicity.

Conclusion

The Lipo-MIT-based regimens demonstrate preliminary efficacy in R/R AML, particularly in those who relapsed after allo-HSCT, though hematologic toxicity warrants careful monitoring.

Clinical Trial Registration: Clinicaltrials.gov Identifier: NCT04645199 in November 27, 2020.